{"doi":"10.14713/arestyrurj.v1i3.177","title":"Pulmonary Inflammation and Injury in a Mouse Model of Non-Alcoholic Steatohepatitis","abstract":"Non-alcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects millions of individuals in the United States, of which approximately twenty percent of cases progress to non-alcoholic steato-hepatitis (NASH). NASH is characterized by macro-vascular steatosis and persistent inflammation in the liver, which can lead to fibrosis. Evidence suggests potential effects of NAFLD and NASH on the devel-opment of pulmonary pathologies, but the interaction between the liver and the lung is not well under-stood. In this study, we assessed the impact of NASH development on lung inflammation and fibrosis over time. Male C57BL/6J mice were fed control (10% kCal) or high-fat (HFD) (60% kCal) diets. Liver tissue, lung tissue, and bronchoalveolar lavage (BAL) fluid were collected after 1, 3, and 6 months of feeding. Histopathologic evaluation of livers from HFD-fed mice at 6 months confirmed the development of NASH. In the lung, we observed histopathologic al-terations, including inflammatory cell infiltration, li-pid-laden macrophages, septal damage, and epi-thelial thickening at 6 months. Gene expression anal-ysis of whole lung tissue revealed changes in genes related to inflammation (IL-1B), fibrosis (CTGF), and lipid metabolism (ApoA1). These results characterize an association of pulmonary complications during simple steatosis to NASH transition, suggesting lung-liver crosstalk.","journal":"Aresty Rutgers Undergraduate Research Journal","year":2021,"id":226946,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9626,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":776851,"name":"Alexa Murray","orcid":"0000-0001-6133-6710","position":1,"is_corresponding":false},{"id":331089,"name":"Laura E. Armstrong","orcid":"0000-0002-7351-0701","position":2,"is_corresponding":false},{"id":305847,"name":"Bo Kong","orcid":"0000-0002-8200-7817","position":3,"is_corresponding":false},{"id":246449,"name":"Grace L. Guo","orcid":"0000-0002-2666-0635","position":4,"is_corresponding":false},{"id":492158,"name":"Andrew J. Gow","orcid":"0000-0003-0876-5158","position":5,"is_corresponding":false},{"id":304790,"name":"Debra L. Laskin","orcid":"0000-0003-1832-7311","position":6,"is_corresponding":false},{"id":830337,"name":"Tanvi Banota","orcid":"0000-0003-2389-1136","position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":null,"created_at":"2026-07-18T23:54:38.004707Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}